Edurans strain M4-5 isolated from human colonic flora attenuates intestinal inflammation

Diseases of the Colon and Rectum

Volumn 53, Issue 12, 2010, Pages 1676-1686

  Avram Hananel, Liraz ^a   Stock, Julia ^b   Parlesak, Alex ^b   Bode, Cristiana ^b   Schwartz, Betty ^a  

^a HEBREW UNIVERSITY OF JERUSALEM   (Israel)

^b UNIVERSITY OF HOHENHEIM   (Germany)

Author keywords

Butyrate; Cytokines; Enterococcus durans; Inflammatory bowel disease; Prevention; Probiotics

Indexed keywords

BUTYRIC ACID; DEXTRAN SULFATE; INTERLEUKIN 10; INTERLEUKIN 6; INTERLEUKIN 8; MYELOPEROXIDASE; PROBIOTIC AGENT; TUMOR NECROSIS FACTOR ALPHA; BUTYRIC ACID DERIVATIVE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ARTICLE; BACTERIAL STRAIN; CELL COMPARTMENTALIZATION; COCULTURE; COLITIS; COLON FLORA; DISEASE ACTIVITY; ENTEROCOCCUS; ENTEROCOCCUS DURANS; FEMALE; HISTOLOGY; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; WEIGHT REDUCTION; ADULT; ANALYSIS OF VARIANCE; ANIMAL; BAGG ALBINO MOUSE; COLON; ISOLATION AND PURIFICATION; MALE; METABOLISM; MICROBIOLOGY; RANDOMIZATION; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION;

ADULT; ANALYSIS OF VARIANCE; ANIMALS; BUTYRATES; COCULTURE TECHNIQUES; COLITIS; COLON; ENTEROCOCCUS; HUMANS; INTERLEUKIN-10; INTERLEUKIN-6; INTERLEUKIN-8; MALE; MICE; MICE, INBRED BALB C; RANDOM ALLOCATION; REVERSE TRANSCRIPTASE POLYMERASE CHAIN REACTION; TUMOR NECROSIS FACTOR-ALPHA;

EID: 78651487211     PISSN: 00123706     EISSN: 15300358     Source Type: Journal    
DOI: 10.1007/DCR.0b013e3181f4b148     Document Type: Article

References (36)

1. Radtke F, Clevers H. Self-renewal and cancer of the gut: two sides of a coin. Science. 2005;307:1904-1909.
2. McConnell BB, Yang VW. The role of inflammation in the pathogenesis of colorectal Cancer. Curr Colorectal Cancer Rep. 2009;5:69-74.
3. Deem RL, Shanahan F, Targan SR. Triggered human mucosal T cells release tumour necrosis factor-alpha and interferongamma which kill human colonic epithelial cells. Clin Exp Immunol. 1991;83:79-84.
4. Shanahan F. Inflammatory bowel disease: immunodiagnostics, immunotherapeutics, and ecotherapeutics. Gastroenterology. 2001;120:622-635.
5. Rachmilewitz D, Katakura K, Karmeli F, et al. Toll-like receptor 9 signaling mediates the anti-inflammatory effects of probiotics in murine experimental colitis. Gastroenterology. 2004;126:520-528.
6. Podolsky DK. Inflammatory bowel disease. N Engl J Med. 2002;347:417-429.
7. Shanahan F. Probiotics in inflamatory bowel disease. Gut. 2001;48:609.
8. Hooper LV, Gordon JI. Commensal host-bacterial relationships in the gut. Science. 2001;292:1115-1118.
9. Teitelbaum JE, Walker WA. Nutritional impact of pre-and probiotics as protective gastrointestinal organisms. Annu Rev Nutr. 2002;22:107-138.
10. Sheil B, Shanahan F, O'Mahony L. Probiotic effects on inflammatory bowel disease. J Nutr. 2007;137:819S-824S.
11. Hedin C, Whelan K, Lindsay JO. Evidence for the use of probiotics and prebiotics in inflammatory bowel disease: a review of clinical trials. Proc Nutr Soc. 2007;66:307-315.
12. Sans M. Probiotics for inflammatory bowel disease: a critical appraisal. Dig Dis. 2009;27(suppl 1):111-114.
13. Gionchetti P, Rizzello F, Venturi A, et al. Oral bacteriotherapy as maintenance treatment in patients with chronic pouchitis: a double-blind, placebo-controlled trial. Gastroenterology. 2000;119:305-309.
14. Holubar SD, Cima RR, Sandborn WJ, Pardi DS. Treatment and prevention of pouchitis after ileal pouch-anal anastomosis for chronic ulcerative colitis. Cochrane Database Syst Rev. 2010;6: CD001176.
15. Wachtershauser A, Stein J. Rationale for the luminal provision of butyrate in intestinal diseases. Eur J Nutr. 2000;39:164-171.
16. Schwartz B, Avivi-Green C, Polak-Charcon S. Sodium butyrate induces retinoblastoma protein dephosphorylation, p16 expression and growth arrest of colon cancer cells. Mol Cell Biochem. 1998;188:21-30.
17. Luhrs H, Gerke T, Boxberger F, et al. Butyrate inhibits interleukin-1-mediated nuclear factor-kappa B activation in human epithelial cells. Dig Dis Sci. 2001;46:1968-1973.
18. Raz I, Gollop N, Polak-Charcon S, Schwartz B. Isolation and characterisation of new putative probiotic bacteria from human colonic flora. Br J Nutr. 2007;97:725-734.
19. Haller D, Bode C, Hammes WP, et al. Non-pathogenic bacteria elicit a differential cytokine response by intestinal epithelial cell/leucocyte co-cultures. Gut. 2000;47:79-87.
20. Okayasu I, Hatakeyama S, Yamada M, et al. A novel method in the induction of reliable experimental acute and chronic ulcerative colitis in mice. Gastroenterology. 1990;98:694-702.
21. Parlesak A, Haller D, Brinz S, Baeuerlein A, Bode C. Modulation of cytokine release by differentiated CACO-2 cells in a compartmentalized coculture model with mononuclear leucocytes and nonpathogenic bacteria. Scand J Immunol. 2004;60:477-485.
22. Haller D, Blum S, Bode C, Hammes WP, Schiffrin EJ. Activation of human peripheral blood mononuclear cells by nonpathogenic bacteria in vitro: evidence of NK cells as primary targets. Infect Immun. 2000;68:752-759.
23. Cooper HS, Murthy SN, Shah RS, Sedergran DJ. Clinicopathologic study of dextran sulfate sodium experimental murine colitis. Lab Invest. 1993;69:238-249.
24. Bradley PP, Priebat DA, Christensen RD, Rothstein G. Measurement of cutaneous inflammation: estimation of neutrophil content with an enzyme marker. J Invest Dermatol. 1982;78:206-209.
25. Lavi I, Levinson D, Peri I, et al. Orally administered glucans from the edible mushroom Pleurotus pulmonarius reduce acute inflammation in dextran sulfate sodium-induced experimental colitis. Br J Nutr. 2010;103:393-402.
26. Jijon H, Backer J, Diaz H, et al. DNA from probiotic bacteria modulates murine and human epithelial and immune function. Gastroenterology. 2004;126:1358-1373.
27. Rachmilewitz D, Karmeli F, Takabayashi K, et al. Immunostimulatory DNA ameliorates experimental and spontaneous murine colitis. Gastroenterology. 2002;122:1428-1441.
28. Lee J, Rachmilewitz D, Raz E. Homeostatic effects of TLR9 signaling in experimental colitis. Ann N Y Acad Sci. 2006;1072:351-355.
29. Luhrs H, Gerke T, Schauber J, et al. Cytokine-activated degradation of inhibitory kappaB protein alpha is inhibited by the short-chain fatty acid butyrate. Int J Colorectal Dis. 2001;16:195-201.
30. Luhrs H, Kudlich T, Neumann M, et al. Butyrate-enhanced TNFalpha-induced apoptosis is associated with inhibition of NF-kappaB. Anticancer Res. 2002;22:1561-1568.
31. Luhrs H, Gerke T, Muller JG, et al. Butyrate inhibits NF-kappaB activation in lamina propria macrophages of patients with ulcerative colitis. Scand J Gastroenterol. 2002;37:458-466.
32. Luhrs H, Hock R, Schauber J, et al. Modulation of HMG-N2 bindingtochromatinbybutyrate-inducedacetylationinhuman colon adenocarcinoma cells. Int J Cancer. 2002;97:567-573.
33. Melgar S, Karlsson L, Rehnstrom E, et al. Validation of murine dextran sulfate sodium-induced colitis using four therapeutic agents for human inflammatory bowel disease. Int Immunopharmacol. 2008;8:836-844.
34. Shibolet O, Karmeli F, Eliakim R, et al. Variable response to probiotics in two models of experimental colitis in rats. Inflamm Bowel Dis. 2002;8:399-406.
35. McAlindon ME, Hawkey CJ, Mahida YR. Expression of interleukin 1 beta and interleukin 1 beta converting enzyme by intestinal macrophages in health and inflammatory bowel disease. Gut. 1998;42:214-219.
36. Akira S, Hirano T, Taga T, Kishimoto T. Biology of multifunctional cytokines: IL 6 and related molecules (IL 1 and TNF). FASEB J. 1990;4:2860-2867.